Articles On Race Oncology (ASX:RAC)

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, that made announcements today.   ICYMI Leade...

It's been a strong session for the All Ordinaries Index (ASX: XAO) and most ASX All Ords shares so far this Thursday. At present, the All Ords has gained a healthy 0.57%, lifting the index to back over 7,200 points. But let's talk about tw...

Welcome to Thursday. The ASX is set to rise with ASX200 futures being 28pts higher (up 0.40 per cent) near 8:30 am AEDT. It was a mixed session overnight in the US. The S&P 500 finished up 0.10 per cent; the NASDAQ up 0.08 per cent....

The S&P/ASX 200 Index (ASX: XJO) has finally broken its November winning streak, and given investors their first red day since Monday 30 October. After a stro...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small decline. At the time of writing, the benchmark index is down 0.2% to 6,983 points. Four ASX shares that are not letting that hold them back are liste...

The Race Oncology Ltd (ASX: RAC) share price is catching the eye on Tuesday. In morning trade, the ASX All Ords biotech share is up 16% to $1.05. Why is this ASX All Ords biotech share on a tear? Investors have been buying the oncology foc...

Now could be the time to pounce on Universal Store Holdings Ltd (ASX: UNI) shares. That's the view of analysts at Bell Potter, which have just initiated coverage on the ASX share. What is the broker saying about this ASX share? Bell Potter...

ASX200 closes +1.13% higher Property stocks, Industrials and IT Sector gain more than 2% Small caps led by takeover target MCM   The Australian sharemarket has ended the first week of November with another stout performance, momentarily a...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

The ASX200 performed consistently holding at about .4 of a per cent up throughout the day. IT was the best performer, up nearly 1.5 per cent – while healthcare stocks had an off day, down almost 1.2 per cent. In the green Mining gi...

The ASX200 is up point four of a per cent so far today, despite significant falls for the energy sector, down nearly 3.5 per cent and materials which has also dropped nearly three per cent. In company news, mining giant Rio Tinto (ASX:RI...

Race Oncology (ASX:RAC) completes a series of preclinical animal and laboratory studies using its novel bisantrene formulation, RC220 It revealed the drug can stop crystallisation in the body and prevent vein inflammation or damage when...

The Race Oncology Ltd (ASX: RAC) share price is having a very strong session. In morning trade, the ASX All Ords share is up an impressive 12% to 86 cents. Why is this ASX All Ords share rising? Investors have been buying the oncology comp...

Race Oncology (ASX:RAC) has announced that Laurus Labs (has successfully produced its first batch of bisantrene dihydrochloride.

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Race Oncology (ASX:RAC) produces its first batch of bisantrene dihydrochloride under cGMP standards with its partner Laurus Labs This achievement paves the way for Race’s flagship drug RC220 RAC’s next steps include transferring the c...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Race Oncology (RAC) has shown once again that a combination of bisantrene with other chemodrugs leads to a more successful cancer plan for patients A wide range of human cancer cell lines were tested with combined dosages with 113 of 14...

The market may be falling for a fourth day in a row, but that hasn't stopped a couple of ASX healthcare shares from charging higher today. Here's what is getting investors excited about them on Wednesday: Race Oncology Ltd (ASX: RAC) The...

According to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO defines cancer as a generic term for a large group of diseases that can affect any part of the body with malignant tumours and neoplasms. W...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

The S&P ASX 200 was down 0.73% in August with mid caps and small caps down 1.3% for the month Eight of 11 sectors down in August with consumer discretionary leading winners and utilities the laggards Tech stock 4DS Memory rises more th...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Race Oncology (RAC) announces that Dr Peter Smith assumes the role of Executive Director following Damian Clarke-Bruce’s resignation as CEO Dr John Cullity is retiring from his Non-Executive Director role Dr Daniel Tillett joins as a...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

MoneyTalks is Stockhead’s regular recap of the ASX stocks, sectors and trends that fund managers and analysts are looking at right now. Today we hear from Andrew Chapman, managing director of Merchant Group Australia.   What sector is hot r...

ASX benchmark falls 0.86% for the day, dragged down by bad news from China. Telcos, Energy and InfoTech tried their best, but the overall gloom was too much to fight. Lithium Universe (ASX:LU7) banks a solid market debut as it kicks off i...

Race Oncolocy’s new corporate strategy has been designed to maximise the inherent value of its core asset bisantrene RC220 for both its cancer-fighting and cardio-protective properties. Clinical stage global biotech Race Oncology (ASX:RAC)...

Recce Pharma surges 20pc on anecdotal results Emyria launches a ketamine-assisted therapy (KAT) program Race Oncology unveils new corporate strategy   Recce surges on anecdotal results Recce Pharma (ASX:RCE) raced higher by more than 20%...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Race Oncology (RAC) receives an additional $1.66 million in an R&D Tax Incentive Refund from the ATO for FY22 The refund relates to successful R&D activities conducted in overseas jurisdictions during the financial year RAC M...

Race Oncology executes agreement with leading global contract development and manufacturing organisation, Ardena as additional partner for GMP manufacturing of flagship RC220 bistanrene formulation Ardena has a long track record of providi...

Race Oncology (RAC) partners with Ardena to bolster the manufacturing capabilities of its flagship intravenous (IV) formulation of bisantrene, RC220 The collaboration serves as a primary source for EU-compliant supplies of RC220 in Euro...

Race executes worldwide license agreement with City of Hope, one of the largest cancer research and treatment organisations in the United States. Under the agreement, Race will exclusively secure rights to a City of Hope patent application...

Race executes worldwide license agreement with City of Hope, one of the largest cancer research and treatment organisations in the United States. Under the agreement, Race will exclusively secure rights to a City of Hope patent application...

Bod Science provided a ‘landmark update’ on its Phase IIB insomnia clinical trial Neurotech received an ethics approval to begin Phase I/II clinical trial Incannex intends to list all its shares on the Nasdaq   Bod Science provides ‘landm...

The ASX is expected to kick off the week on a positive after last week’s tumble on Wall Street, which left stocks lower at closing after the US June jobs report strengthened possibilities for a rate rise. Important news to watch out for...

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Orphan diseases are those impacting less than 200,000 patients Orphan drug designation ensures an exclusivity period for pharma companies The average orphan drug in the US retails for US$7,000 per month   Rare or ‘Orphan’ diseases affect...

I’m about to tell you about some excellent All Ordinaries (ASX: XAO), or All Ords, ASX shares that I think are very cheap. Certainly, there’s been plenty of volatility in recent times, but this gives us an opportunity to buy shares at...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

If you’re looking to take advantage of recent weakness in the lithium industry to make some investments, then you might want to check out the three buy-rated ASX 200 lithium shares listed below. Here’s what analysts are saying about th...

A key part of the Australian economy is the mining sector. In light of this, it will come as little surprise to learn that there are a large number of mining shares listed on the ASX. But given the vast options it can be hard to decide whi...

The S&P/ASX 200 Index (ASX: XJO) ended the week on a high, rising 0.51% to finish the session at 7,361.6 points – its highest close since early March. That also leaves it 1.98% higher week-on-week. It followed a strong session over o...

S&P/ASX 200 Index (ASX: XJO) gold shares are enjoying some healthy tailwinds from a fast-rising gold price. So far in 2023, the S&P/ASX All Ordinaries Gold Index (ASX: XGD), which also contains some smaller gold stocks outside of...

The materials sector has recovered to make a slight gain this morning, as the impact of the now-category-three cyclone Ilsa in Port Hedland and the Pilbara region appears to be lower than expected. WA1 Resources (WA1) has put its drillin...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a positive note. At the time of writing, the benchmark index is up 0.4% to 7,351.1 points. Four ASX shares that are climbing more than most today are...

Race Oncology (RAC) flags the multi-billion-dollar market potential of its Zantrene drug as a potential cardio-protective agent and an anti-cancer agent The company says an independent analysis suggests a use case in nearly its entire t...